BRPI0512514A - composto, antagonista para receptores de crf, e, uso de um composto - Google Patents

composto, antagonista para receptores de crf, e, uso de um composto

Info

Publication number
BRPI0512514A
BRPI0512514A BRPI0512514-6A BRPI0512514A BRPI0512514A BR PI0512514 A BRPI0512514 A BR PI0512514A BR PI0512514 A BRPI0512514 A BR PI0512514A BR PI0512514 A BRPI0512514 A BR PI0512514A
Authority
BR
Brazil
Prior art keywords
crf
compound
receptor antagonist
diseases
crf receptor
Prior art date
Application number
BRPI0512514-6A
Other languages
English (en)
Inventor
Atsuro Nakazato
Taketoshi Okubo
Dai Nozawa
Ludo E J Kennis
Marcel F L De Bruyn
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of BRPI0512514A publication Critical patent/BRPI0512514A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO, ANTAGONISTA PARA RECEPTORES DE CRF, E, USO DE UM COMPOSTO Um objetivo da presente invenção é fornecer um antagonista contra receptores de CRF que seja eficaz como um agente terapêutico ou profilático para doenças em que o CRF é considerado estar envolvido, tal como depressão, ansiedade, doença de Alzheimer, doença de Parkinson, coréia de Huntington, distúrbios alimentares, hipertensão, doenças gastrointestinais, dependência de medicamento, infarto cerebral, isquemia cerebral, edema cerebral, ferimento externo cefálico, inflamação, doenças relacionadas com a imunidade, alopecia, síndrome do intestino irritável, distúrbios do sono, epilepsia, dermatites, esquizofrenia, dor, etc. ¢SOLUçãO! Um derivado de pirrolpirimidina ou pirrolpiridina substituído com tetraidropiridina representado pela seguinte fórmula ¢I!: tem uma afinidade alta quanto a receptores de CRF e é eficaz conta doenças em que CRF é considerado estar envolvido.
BRPI0512514-6A 2004-06-25 2005-06-24 composto, antagonista para receptores de crf, e, uso de um composto BRPI0512514A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004188129 2004-06-25
PCT/JP2005/012141 WO2006001501A1 (en) 2004-06-25 2005-06-24 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists

Publications (1)

Publication Number Publication Date
BRPI0512514A true BRPI0512514A (pt) 2008-03-11

Family

ID=34971524

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512514-6A BRPI0512514A (pt) 2004-06-25 2005-06-24 composto, antagonista para receptores de crf, e, uso de um composto

Country Status (14)

Country Link
US (1) US20070293670A1 (pt)
EP (1) EP1781652A1 (pt)
JP (1) JP2008503443A (pt)
KR (1) KR20070024632A (pt)
CN (1) CN1972941A (pt)
AU (1) AU2005257486A1 (pt)
BR (1) BRPI0512514A (pt)
CA (1) CA2568802A1 (pt)
IL (1) IL179605A0 (pt)
MX (1) MXPA06015002A (pt)
NO (1) NO20070467L (pt)
RU (1) RU2007102683A (pt)
WO (1) WO2006001501A1 (pt)
ZA (1) ZA200610043B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066142A2 (en) * 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists
ES2282986T3 (es) 2004-01-06 2007-10-16 Taisho Pharmaceutical Co., Ltd Derivados de triaza-ciclopenta(cd)indeno.
CA2552598A1 (en) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
US7738257B2 (en) * 2006-12-13 2010-06-15 Intel Corporation Microelectronic device including bridging interconnect to top conductive layer of passive embedded structure and method of making same
DE102007035367A1 (de) * 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008013587A1 (de) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009143992A1 (de) * 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1689161A (en) * 1925-11-06 1928-10-23 Charles A Skultin Highway crossing
US2941454A (en) * 1957-10-21 1960-06-21 Cedeno Arturo Olivero Traffic intersection
US3945745A (en) * 1974-08-05 1976-03-23 Chang Amos I T Traffic flow control systems
EP0976745B1 (en) * 1997-03-26 2003-08-13 Taisho Pharmaceutical Co., Ltd 4-tetrahydropyridylpyrimidine derivatives
ATE297393T1 (de) * 1999-03-11 2005-06-15 Taisho Pharmaceutical Co Ltd Carbamoyltetrahydropyridin-derivate
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US20020076276A1 (en) * 2000-12-15 2002-06-20 Troemel David Eric Butzek-troemel roundabout or "spiralabout"
US7279474B2 (en) * 2001-04-30 2007-10-09 Glaxo Group Limited Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF)
TWI270549B (en) * 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
CA2552598A1 (en) * 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
ES2282986T3 (es) * 2004-01-06 2007-10-16 Taisho Pharmaceutical Co., Ltd Derivados de triaza-ciclopenta(cd)indeno.

Also Published As

Publication number Publication date
CN1972941A (zh) 2007-05-30
KR20070024632A (ko) 2007-03-02
CA2568802A1 (en) 2006-01-05
WO2006001501A1 (en) 2006-01-05
NO20070467L (no) 2007-01-24
AU2005257486A1 (en) 2006-01-05
RU2007102683A (ru) 2008-07-27
EP1781652A1 (en) 2007-05-09
JP2008503443A (ja) 2008-02-07
IL179605A0 (en) 2007-05-15
ZA200610043B (en) 2008-06-25
US20070293670A1 (en) 2007-12-20
MXPA06015002A (es) 2007-02-08

Similar Documents

Publication Publication Date Title
BRPI0512514A (pt) composto, antagonista para receptores de crf, e, uso de um composto
BRPI0512418A (pt) derivado de pirrolpirimidina ou pirrolpiridina substituìdo com um grupo amino cìclico, compostos, antagonista para receptores de crf, uso de um derivado de pirrolpirimidina ou pirrolpiridina substituìdo com um grupo amino cìclico, de um sal do mesmo e de seu hidrato farmaceuticamente aceitáveis
BR0307587A (pt) Derivado de pirroloprimida ou porrolopiridina substituìdo com um grupo amino cìclico, compostos, antagonista para receptores de crf, e, uso de um derivado de pirroloprimidina ou derivado de pirrolopiridina substituìdo com um grupo amino cìclico, um sal farmaceuticamente aceitável do mesmo ou seu hidrato
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
BRPI0719361B8 (pt) composto, composição farmacêutica, e, uso do composto
MX2012007013A (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
BRPI0919876A8 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
MX2015008481A (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
BR112012000204A8 (pt) Composição farmacêutica em forma de dosagem unitária que compreende apomorfina e seu uso
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
UA96458C2 (ru) Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
CY1111128T1 (el) Στεροειδη παραγωγα 17-φωσφορου χρησιμα ως τροποποιητες υποδοχεων προγεστερονης
AU2012357747A8 (en) TRPM8 antagonists
DE602005000676D1 (de) Triazacyclopentaäcdüindenderivate
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
EA201170563A1 (ru) Метиленамины тиено[2,3-d]пиримидина и их применение в качестве антагонистов рецепторов a2a аденозина
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
WO2005066142A3 (en) Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]